Literature DB >> 16489361

Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia.

J R Passweg1, W S Pérez, M Eapen, B M Camitta, E Gluckman, W Hinterberger, J M Hows, J C W Marsh, R Pasquini, H Schrezenmeier, G Socié, M-J Zhang, C Bredeson.   

Abstract

For patients with acquired severe aplastic anemia without a matched sibling donor and not responding to immunosuppressive treatment, bone marrow transplantation from a suitable alternative donor is often attempted. We examined risks of graft failure, graft-versus-host disease and overall survival after 318 alternative donor transplants between 1988 and 1998. Sixty-six patients received allografts from 1-antigen and 20 from >1-antigen mismatched related donors; 181 from matched and 51 from mismatched unrelated donors. Most patients were young, had had multiple red blood cell transfusions and poor performance score at transplantation. We did not observe differences in risks of graft failure and overall mortality by donor type. The probabilities of graft failure at 100 days after 1-antigen mismatched related donor, >1-antigen mismatched related donor, matched unrelated donor and mismatched unrelated donor transplants were 21, 25, 15 and 18%, respectively. Corresponding probabilities of overall survival at 5 years were 49, 30, 39 and 36%, respectively. Although alternative donor transplantation results in long-term survival, mortality rates are high. Poor performance score and older age adversely affect outcomes after transplantation. Therefore, early referral for transplantation should be encouraged for patients who fail immunosuppressive therapy and have a suitable alternative donor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489361     DOI: 10.1038/sj.bmt.1705299

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  31 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

2.  Allogeneic hematopoietic cell transplantation for severe aplastic anemia: similar long-term overall survival after transplantation with related donors compared to unrelated donors.

Authors:  B K Mortensen; N Jacobsen; C Heilmann; H Sengeløv
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

Review 3.  The diagnosis and treatment of aplastic anemia: a review.

Authors:  Maurizio Miano; Carlo Dufour
Journal:  Int J Hematol       Date:  2015-04-03       Impact factor: 2.490

4.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

Authors:  Michael A Pulsipher; Neal S Young; Jakub Tolar; Antonio M Risitano; H Joachim Deeg; Paolo Anderlini; Rodrigo Calado; Seiji Kojima; Mary Eapen; Richard Harris; Phillip Scheinberg; Sharon Savage; Jaroslaw P Maciejewski; Ramon V Tiu; Nancy DiFronzo; Mary M Horowitz; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

Review 5.  Clinical management of aplastic anemia.

Authors:  Amy E Dezern; Robert A Brodsky
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

6.  Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years.

Authors:  Xia Qin; Yi-Ping Zhu; Cheng-Juan Luo; Ming Zhou; Ke Huang; Chun Chen; Wei-Ping Zhang; Yuan Sun; Rong-Mu Luo; Xiang-Feng Tang; Ting Yang; Xian-Min Song; Shao-Yan Hu; Zi-Min Sun; Jiong Hu; Shun-Qing Wang; Jing Chen
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

7.  The Third Consensus Conference on the treatment of aplastic anemia.

Authors:  Seiji Kojima; Shinji Nakao; Neal Young; Andrea Bacigalupo; Gerard Gerard; Naoto Hirano; Jaroslaw Maciejewski; Joachim Deeg; Judith Marsh; Feng-Kui Zhang; Jong Wook Lee; Keiya Ozawa
Journal:  Int J Hematol       Date:  2011-05-27       Impact factor: 2.490

8.  Haploidentical TCR A/B and B-cell depleted hematopoietic SCT in pediatric SAA and aspergillosis.

Authors:  M Tumino; C Mainardi; M Pillon; E Calore; M V Gazzola; R Destro; A Strano; S Varotto; F Gregucci; G Basso; C Messina
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

9.  Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy.

Authors:  L Gao; Y Li; Y Zhang; X Chen; L Gao; C Zhang; Y Liu; P Kong; Q Wang; Y Su; C Wang; S Wang; B Li; A Sun; X Du; D Zeng; J Li; H Liu; X Zhang
Journal:  Bone Marrow Transplant       Date:  2014-01-27       Impact factor: 5.483

10.  Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Neal S Young
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.